Loading...
01/11 16:20
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call summary provides a mixed picture. While financial performance shows growth, the guidance is weaker, and there are regulatory and competitive pressures. The Q&A highlights interest in new products but lacks clarity on financial impacts. The $100 million share repurchase is positive, but market conditions and customer demand softness temper expectations. Considering the company's market cap, the stock is likely to remain stable, with a neutral prediction in the -2% to 2% range.
Total Revenue $106 million, representing 10% growth year-over-year.
Total Bookings $118.2 million, which increased 12% year-over-year.
Software Revenue $46.4 million, an increase of 18% year-over-year.
Services Revenue $59.6 million, up 4% year-over-year.
Adjusted EBITDA $34.8 million, an increase from $29.1 million year-over-year.
Net Income $4.7 million, compared to a net loss of $4.7 million in the prior year.
Adjusted Net Income $22.4 million, compared to $16.5 million year-over-year.
Diluted Earnings Per Share $0.03, compared to a loss of $0.03 per share in the prior year.
Adjusted Diluted Earnings Per Share $0.14, compared to $0.10 year-over-year.
Cash and Cash Equivalents $179.1 million as of March 31, 2025.
Outstanding Borrowings $294.8 million on term loan.
Share Repurchase $100 million authorized, with approximately $25 million repurchased to date.
New Product Launch: Certara has created a biosimulation solution called Non-Animal Navigator for preclinical monoclonal antibody development, leveraging the Simcyp simulator and QSP modeling group.
Software Update: On April 1, Certara announced the 24th version of its Simcyp Simulator, featuring new capabilities including an expanded library for drug-drug interactions and enhancements for modeling special populations.
Market Expansion: Certara is experiencing increased inbound interest from customers following the FDA's announcement to phase out animal testing, indicating a potential market expansion for their services.
Operational Efficiency: Certara's adjusted EBITDA for Q1 2025 was $34.8 million, with a margin of 33%, benefiting from slower-than-expected hiring.
Strategic Shift: Certara is focusing on integrating AI into its software solutions and expanding its offerings into earlier stages of drug development.
Regulatory Issues: The company faces headwinds from the downstream effects of IRA price controls and potential new trade and healthcare policies from the current administration.
Supply Chain Challenges: There is an erratic capital raising environment for biotechs, which may impact the company's operations and customer base.
Competitive Pressures: The company is experiencing softness in demand from Tier 1 customers in biosimulation services, which could affect revenue growth.
Economic Factors: The overall market conditions remain muted, which presents challenges for the company's commercial performance.
Strategic Investment Plan: Certara will continue to execute its strategic investment plan focusing on the integration of AI into software solutions, building a more integrated software platform, increasing investment in bio stimulation model development, and expanding solutions into earlier stages of drug development.
Biosimulation Solution: Certara has created a biosimulation solution called Non-Animal Navigator for preclinical monoclonal antibody development, leveraging the Simcyp simulator and QSP modeling group.
Leadership Transition: Dr. Adrian McKemey has been appointed as President of Drug Development Solutions, with Patrick Smith transitioning to Senior Vice President of Translational Sciences.
Share Repurchase Authorization: On April 14, Certara announced a $100 million share repurchase authorization to manage capital and drive shareholder value.
Revenue Guidance: Certara expects total revenue in the range of $415 million to $425 million, representing growth of 8% to 10% compared to 2024.
Adjusted EBITDA Margin: Expected adjusted EBITDA margins are between 30% to 32%.
Adjusted EPS Guidance: Certara anticipates adjusted EPS in the range of $0.42 to $0.46 per share.
Chemaxon Contribution: Chemaxon is expected to contribute software revenue of $23 million to $25 million.
Share Repurchase Authorization: On April 14, Certara announced a $100 million share repurchase authorization, allowing for more flexibility in capital management to drive shareholder value.
Share Repurchase Progress: Following the announcement, Certara has repurchased approximately $25 million of the authorized amount to date.
The earnings call revealed strong financial performance, with positive EPS growth and a solid cash position. Despite some deceleration in Tier 1 services, the company is optimistic about CertaraIQ's launch and future growth in software sales, driven by AI integration and market demand. The Q&A session highlighted productivity improvements and a favorable software mix, boosting gross margins. While guidance for services is cautious, the overall sentiment is positive, supported by strategic R&D investments and exposure to growing markets. The market cap suggests moderate volatility, aligning with a 'Positive' rating.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
